|
US20030114410A1
(en)
|
2000-08-08 |
2003-06-19 |
Technion Research And Development Foundation Ltd. |
Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
|
|
GB0521139D0
(en)
*
|
2005-10-18 |
2005-11-23 |
Univ Sheffield |
Therapeutic agent
|
|
CA2647846C
(en)
|
2006-03-31 |
2016-06-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
|
CA2654623C
(en)
|
2006-06-08 |
2016-07-26 |
Chugai Seiyaku Kabushiki Kaisha |
An anti-nr10/il-31ra antibody for use in preventing or treating an inflammatory disease
|
|
SI2185198T1
(sl)
|
2007-08-02 |
2015-04-30 |
Gilead Biologics, Inc. |
Inhibitorji LOX in LOXL2 ter njihova uporaba
|
|
PL2202245T3
(pl)
|
2007-09-26 |
2017-02-28 |
Chugai Seiyaku Kabushiki Kaisha |
Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
|
|
WO2009041613A1
(ja)
|
2007-09-26 |
2009-04-02 |
Chugai Seiyaku Kabushiki Kaisha |
抗体定常領域改変体
|
|
MY185647A
(en)
|
2007-12-05 |
2021-05-27 |
Chugai Pharmaceutical Co Ltd |
Therapeutic agent for pruritus
|
|
KR20160074019A
(ko)
|
2007-12-05 |
2016-06-27 |
추가이 세이야쿠 가부시키가이샤 |
항ｎｒ１０ 항체 및 그의 이용
|
|
KR102269708B1
(ko)
|
2008-04-11 |
2021-06-25 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복 결합하는 항원 결합 분자
|
|
SG190572A1
(en)
*
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
SG191639A1
(en)
|
2008-06-03 |
2013-07-31 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
PE20100054A1
(es)
*
|
2008-06-03 |
2010-03-03 |
Abbott Lab |
Inmunoglobulina con dominio variable dual
|
|
MX2010014574A
(es)
*
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
|
KR20160062207A
(ko)
*
|
2008-12-05 |
2016-06-01 |
추가이 세이야쿠 가부시키가이샤 |
항ｎｒ１０ 항체 및 그의 이용
|
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
US9107935B2
(en)
|
2009-01-06 |
2015-08-18 |
Gilead Biologics, Inc. |
Chemotherapeutic methods and compositions
|
|
US20120071634A1
(en)
|
2009-03-19 |
2012-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody Constant Region Variant
|
|
US9228017B2
(en)
|
2009-03-19 |
2016-01-05 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
BRPI1012195A2
(pt)
*
|
2009-05-01 |
2018-04-24 |
Abbott Lab |
imunoglobulinas de domínio variável duplo e usos das mesmas
|
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
CA2771702A1
(en)
|
2009-08-21 |
2011-02-24 |
Gilead Biologics, Inc. |
Catalytic domains from lysyl oxidase and loxl2
|
|
AR078651A1
(es)
*
|
2009-10-15 |
2011-11-23 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
CA2807014A1
(en)
|
2010-08-03 |
2012-02-09 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
CA2809433A1
(en)
|
2010-08-26 |
2012-03-01 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
EP4231014A3
(en)
|
2010-11-30 |
2024-08-14 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
|
BR112014010008A2
(en)
*
|
2011-10-26 |
2018-09-04 |
Novartis Ag |
monoclonal antibodies, their uses and nucleic acids
|
|
BR112014015851A2
(pt)
|
2011-12-30 |
2019-09-24 |
Abbvie Inc |
proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
|
|
BR112015009961B1
(pt)
|
2012-11-01 |
2020-10-20 |
Abbvie Inc. |
proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende
|
|
MX2015013166A
(es)
|
2013-03-15 |
2015-12-11 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
|
|
US10379127B2
(en)
|
2013-11-27 |
2019-08-13 |
Welcome Receptor Antibodies Pty Ltd |
Marker of cell death
|
|
AU2015318008B2
(en)
|
2014-09-15 |
2021-05-20 |
Amgen Inc. |
Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
MA43918A
(fr)
|
2015-04-14 |
2018-12-05 |
Chugai Pharmaceutical Co Ltd |
Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
|
|
HRP20250972T1
(hr)
|
2015-04-14 |
2025-10-10 |
Chugai Seiyaku Kabushiki Kaisha |
Farmaceutski pripravak za prevenciju i/ili liječenje atopijskog dermatitisa koji sadrži il-31 antagonist kao djelatni sastojak
|
|
JOP20200116A1
(ar)
|
2015-04-24 |
2017-06-16 |
Amgen Inc |
طرق لعلاج أو الوقاية من الصداع النصفي
|
|
GB201509907D0
(en)
*
|
2015-06-08 |
2015-07-22 |
Urosens Ltd |
Antibodies
|
|
EP3304084B1
(en)
|
2015-06-08 |
2022-03-23 |
Arquer Diagnostics Limited |
Methods and kits
|
|
CN107771285A
(zh)
|
2015-06-08 |
2018-03-06 |
阿奎尔诊断有限公司 |
方法
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
TW201805309A
(zh)
|
2016-04-21 |
2018-02-16 |
艾伯維史坦森特瑞斯有限責任公司 |
新穎抗－bmpr1b抗體及使用方法
|
|
GB201707938D0
(en)
|
2017-05-17 |
2017-06-28 |
Univ Sheffield |
Compounds
|
|
EP3774881A1
(en)
|
2018-04-02 |
2021-02-17 |
Amgen Inc. |
Erenumab compositions and uses thereof
|
|
EP3864039B1
(en)
*
|
2018-10-08 |
2023-12-06 |
The UAB Research Foundation |
Neuroendocrine cancer targeted therapy
|
|
GB201818649D0
(en)
|
2018-11-15 |
2019-01-02 |
Univ Sheffield |
Compounds
|
|
GB201818651D0
(en)
|
2018-11-15 |
2019-01-02 |
Univ Sheffield |
Compounds
|
|
EP4062933A4
(en)
|
2019-11-20 |
2023-12-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing preparation
|
|
CN112920267B
(zh)
*
|
2021-03-09 |
2021-08-13 |
北京康乐卫士生物技术股份有限公司 |
一种抗人乳头瘤病毒31型的单克隆中和抗体及其应用
|
|
WO2024102912A1
(en)
*
|
2022-11-10 |
2024-05-16 |
The Children's Medical Center Corporation |
Cgrp/ramp1 blockade to treat endometriosis-associated pain and reduce endometriosis lesions
|
|
GB202303531D0
(en)
*
|
2023-03-10 |
2023-04-26 |
Fusion Antibodies Plc |
Antibodies and uses thereof
|